Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rigosertib sodium (ON-01910) 是一种选择性的非 ATP 竞争性PLK1抑制剂,IC50值为 9 nM。它是一种多激酶抑制剂和选择性抗癌剂,通过抑制PI3K/Akt 途径诱导细胞凋亡,促进组蛋白 H2AX 的磷酸化并诱导细胞周期中的 G2/M 期停滞。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 281 | 现货 | ||
2 mg | ¥ 397 | 现货 | ||
5 mg | ¥ 578 | 现货 | ||
10 mg | ¥ 997 | 现货 | ||
25 mg | ¥ 1,970 | 现货 | ||
50 mg | ¥ 3,660 | 现货 | ||
100 mg | ¥ 6,230 | 现货 | ||
500 mg | ¥ 12,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 591 | 现货 |
产品描述 | Rigosertib sodium (ON-01910), a non-ATP-competitive inhibitor of PLK1(IC50=9 nM), exhibits 30-fold higher specificity activity over Plk2 and no effect on Plk3. |
靶点活性 | CDK1:260 nM (IC50), Fyn:182 nM (IC50), PDGFR:18 nM (IC50), FLK1:42 nM (IC50), PLK1:9 nM (IC50), PLK2:260 nM (IC50), BCR-ABL:32 nM (IC50), Src:155 nM (IC50) |
激酶实验 | In vitro enzyme assays for PLK1: Recombinant PLK1 (10 ng) is incubated with different concentrations of Rigosertib in a 15 μL reaction mixture (50 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 2 mM Dithiothreitol, 0.01% NP-40 [pH 7.5]) for 30 min at room temperature. Kinase reactions are performed for 20 min at 30 °C in a volume of 20 μL (15 μL enzyme + inhibitor, 2 μL 1 mM ATP), 2 μL of γ32P-ATP (40 μCi), and 1 μL of recombinant Cdc25C (100 ng) or casein (1 μg) substrates. Reactions are terminated by boiling for 2 min in 20 μL of 2× Laemmli buffer. Phosphorylated substrates are separated by 18% SDS-PAGE. The gels are dried and exposed to X-ray film for 3-10 min. |
细胞实验 | Cells are grown in either DMEM or RPMI supplemented with 10% fetal bovine serum and 1 unit/mL penicillin-streptomycin solution. Tumor cells are plated into six-well dishes at a density of 1 × 105cells/mL/well, and Rigosertib is added 24 hours later at various concentrations. Cell counts are determined from duplicate wells after 96-hour of treatment. The total number of viable cells is determined by trypan blue exclusio(Only for Reference) |
别名 | Rigosertib, Estybon, ON-01910 |
分子量 | 473.47 |
分子式 | C21H24NNaO8S |
CAS No. | 592542-60-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 87 mg/mL (183.7 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 88 mg/mL (185.9 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 2.1121 mL | 10.5603 mL | 21.1207 mL | 52.8017 mL |
5 mM | 0.4224 mL | 2.1121 mL | 4.2241 mL | 10.5603 mL | |
10 mM | 0.2112 mL | 1.056 mL | 2.1121 mL | 5.2802 mL | |
20 mM | 0.1056 mL | 0.528 mL | 1.056 mL | 2.6401 mL | |
50 mM | 0.0422 mL | 0.2112 mL | 0.4224 mL | 1.056 mL | |
100 mM | 0.0211 mL | 0.1056 mL | 0.2112 mL | 0.528 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Rigosertib sodium 592542-60-4 Apoptosis Cell Cycle/Checkpoint PI3K/Akt/mTOR signaling PLK PI3K Rigosertib Estybon inhibit Phosphoinositide 3-kinase ON-01910 Inhibitor ON01910 ON 01910 Polo-like Kinase (PLK) inhibitor